aTyr Pharma Class Action Notice: Lead Plaintiff Deadline December 8
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 59 minutes ago0mins
- Class Action Notice: Rosen Law Firm reminds investors who purchased aTyr Pharma stock between January 16 and September 12, 2025, to apply as lead plaintiffs by December 8, 2025, to represent other shareholders in the litigation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Lawsuit Background: The complaint alleges that aTyr Pharma misled investors by providing overwhelmingly positive statements while concealing significant adverse facts regarding the efficacy of Efzofitimod, resulting in investor losses when the truth emerged.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and expertise in handling such cases.
ATYR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ATYR
Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 8.00 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
2 Buy
7 Hold
0 Sell
Hold
Current: 0.824
Low
1.00
Averages
8.00
High
20.00
Current: 0.824
Low
1.00
Averages
8.00
High
20.00
Leerink
Faisal Khurshid
Outperform
maintain
$NULL
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$NULL
2025-09-15
maintain
Outperform
Reason
Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
2025-09-15
Reason
Cantor Fitzgerald
Price Target
2025-09-15
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.
Leerink
Faisal Khurshid
Outperform
to
Market Perform
downgrade
$16 -> $1
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$16 -> $1
2025-09-15
downgrade
Outperform
to
Market Perform
Reason
Leerink analyst Faisal Khurshid downgraded aTyr Pharma to Market Perform from Outperform with a price target of $1, down from $16, after the company reported that the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The firm had been positive heading into the "highly binary" readout, but tells investors "we were wrong" after topline results showed no statistically significant difference in steroid reduction. The firm isn't sure there is a path forward for efzo given the miss on the primary endpoint and unclear clinical relevance of quality-of-life improvement, the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2025-09-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-09-15
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded aTyr Pharma to Neutral from Buy without a price target after the company's Phase 3 EFZO-FIT study evaluating lead asset efzofitimod for the treatment of pulmonary sarcoidosis missed the primary endpoint. "Many open questions remain regarding a path forward," the analyst tells investors in a research note. The firm cites the lack of regulatory visibility for the downgrade.
See All Ratings
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key allegations against aTyr Pharma in the lawsuits?
Why did aTyr Pharma's stock drop by 83.2% in September 2025?
How might the lawsuits affect aTyr Pharma's stock performance in the future?
Will the legal actions against aTyr Pharma impact investor confidence long-term?